Anzeige
Mehr »
Login
Samstag, 25.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJTA | ISIN: US74349T1016 | Ticker-Symbol:
1-Jahres-Chart
PROPELLUS INC Chart 1 Jahr
5-Tage-Chart
PROPELLUS INC 5-Tage-Chart
ACCESS Newswire
349 Leser
Artikel bewerten:
(2)

Propellus, Inc.: Propellus Releases Year End Results

Finanznachrichten News

Company also sees strong market environment confirmed by active Q1

RED BANK, NJ / ACCESSWIRE / July 10, 2024 / Propellus Inc., an Oklahoma corporation, (OTC PINK:PRPS), an alternative finance company that specializes in assisting small businesses with their cash flow needs, reported its financial results for its fiscal year ending March 31, 2024.

Higher interest rates, the challenging economic landscape, and tightening credit at most US lending institutions continue to impact small businesses, and many merchants are seeking financing outside traditional channels. "Based on our experience, we feel these market conditions benefit the financing alternatives offered by Propellus, and that has been confirmed by our initial activity in the first quarter," stated Ralph Johnson, CEO. "Company funding activity was the highest it's been in over a year, and our collections increased over 40% in sequential quarters Q4 to Q1", continued Johnson.

During fiscal year 2024, Propellus took the opportunity to complete a capital restructure that had the net effect of reducing the amount of our outstanding common shares from 10,387,116 to 8,996,016, which is a 13% reduction year over year, but represents a 38% reduction from December 31, 2023 after the conversion of over 90% of Convertible Preferred Class A and Class B shares into 4,098,900 common shares at $1.80 per share. With the conclusion of its fiscal year, the Company finalized a write-down of $3,159,221 in predominately pre-Covid non-performing transactions to largely close the chapter on pandemic affected assets acquired during an asset liquidation and exchange in late 2020.

Johnson added, "We also instituted a new corporate dividend policy to provide for the payout of 50% of free monthly cash flow to our common shareholders in the form of a cash distribution. We are experiencing a huge surge in demand and in order to continue serving this increasing market opportunity, we are currently working on several alternatives to potentially expand our capital base by up to $20,000,000. We look forward to increasing our market share and profitability for the benefit of our shareholders during the current fiscal year and beyond."

FY 2024 Highlights

  • Total Revenues during the period totaled $598,629 from $1,408,915 from the prior fiscal year.

  • While Total Expenses during the period increased to $4,820,115 from $2,082,492, excluding the pandemic assets write-down and non cash stock compensation, Operating Expenses fell 37% to $1,328,494 from $2,122,493 in the prior fiscal year.

  • Net Loss during the period increased to $4,221,486 from $673,577 from the prior fiscal year and Profit/(Loss) Per Share during the period increased to ($0.39) from ($0.06) from the prior fiscal year.

About Propellus Inc.: Propellus Inc., is engaged in offering small businesses a variety of financing alternatives usually ranging in amounts between $10,000-$250,000. Such financings include payroll advances, merchant cash advances, accounts receivable factoring, short-term line of credit loans, and other types of loan products and cash flow financing.

CONTACT:

Investor Relations
info@propelluscorp.com

SOURCE: Propellus Inc.



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Diesen Artikel auf Deutsch lesen
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.